Obesity management for kidney TRANSPLANTation (OK-TRANSPLANT 2)

Overview
This research is a smaller pilot study designed to pave the way for a larger clinical trial, with the goal to develop a weight management program tailored to patients with advanced kidney disease and obesity, aiming to support weight loss and improve their chances of receiving a kidney transplant.
For participants in the usual care group, they will only need to complete the informed consent process and a few questions regarding demographics/sarcopenia at the beginning of their time in the study and again 6 months later, at the end. Nothing will be expected of these participants at any other time throughout the study.
Eligibility
To participate in this study, you must:
-
Be 18 years of age or older
-
Have a Body Mass Index (BMI) ≥ 35 kg/m²
-
Be either:
-
Currently receiving dialysis, or
-
Have a >10% risk of progressing to End-Stage Kidney Disease requiring renal replacement therapy (RRT) within 2 years
-
You cannot participate if you:
-
Have a known contraindication to GLP-1 receptor agonist (GLP-1RA) medications, such as:
-
A history of pancreatitis
-
A personal or family history of medullary thyroid cancer
-
A known hypersensitivity to GLP-1RA medications
-
-
Do not have access to drug benefits that cover semaglutide
-
Are pregnant or breastfeeding
-
Have Type 1 diabetes
-
Are currently enrolled in or planning to join another GLP-1RA or GLP-1RA/GIP study
Deadline: 10/31/2025
Study contact: heather.lapier@sjhc.london.on.ca